Table 4.

Linear mixed models for CMR derivatives explained by PET measurements

Model 1	CMR follow-up
	No explanatory factors except PET derivatives N = 560 segments
Outcome	Wall thickening (% AHA-16 segments)			Wall motion (mm AHA-16 segments)			LGE (% transmurality per AHA-16 segments)
PET subacute	β	P	R 2	β	P	R 2	β	P	R2
Extent of severe hypoperfusion (%)	−0.28 [−.38; −.19]	.001	0.07	−0.06 [−.07; −.05]	.001	0.25	0.49 [.44; .53]	.001	0.48
Blood flow (ml·min·g)	62.2 [53.1; 71.3]	.001	0.30	6.0 [5.0; 7.0]	.001	0.25	−38.6 [−44.6; −32.6]	.001	0.28

Model 2	CMR follow-up
	Controlled for: AHA-16 segments, infarct-related artery segments, vascular territory
Outcome	Wall thickening (% AHA-16 segments)			Wall motion (mm AHA-16 segments)			LGE (% transmurality per AHA-16 segments)
PET subacute	β [CI]	P	R 2	β	P	R 2	β	P	R 2
Extent of severe hypoperfusion (%)	−0.36 [−.45; −.27]	.001	0.37	−0.04 [−.05; −.03]	.001	0.66	0.43 [.38; .49]	.001	0.58
Blood flow (ml·min·g)	39.6 [28.5; 50.3]	.001	0.39	4.6 [3.5; 5.2]	.001	0.67	−38.4 [−44.8; −31.9]	.001	0.45

Model 3	CMR follow-up
	Controlled for: AHA-16 segments, sex, vascular territory, infarct-related artery segments, HT, HL, DM, familiar disposition, apoplexia, tobacco, TIMI flow, time from symptom-onset to pPCI
Outcome	Wall thickening (% AHA-16 segments)			Wall motion (mm) AHA-16 segments			LGE (% transmurality per AHA-16 segments)
PET subacute	β [CI]	P	R 2	β	P	R 2	β	P	R 2
Extent of severe hypoperfusi-on (%)	−0.37 [−.47; −.26]	.001	0.42	−0.04 [−.05; −.03]	.001	0.68	0.42 [.37; .48]	.001	0.61
Blood flow (ml·min·g)	38.8 [26.8; 50.8]	.001	0.46	4.5 [3.6; 5.5]	.001	0.65	−38.6 [−45.7; −31.6]	.001	0.49

Mixed-model analyses (model 1, 2, and 3 with increasing complexity due to additional predictive factors and covariates) of CMR-derived wall thickening, wall motion and LGE transmurality per AHA-16 segments

CI, confidence interval; PET, positron emission tomography; LGE, Late gadolinium enhancement; AHA-16, American Heart Association 16-segment model